Cetera Trust Company, N.A Halozyme Therapeutics, Inc. Transaction History
Cetera Trust Company, N.A
- $157 Billion
- Q1 2025
A detailed history of Cetera Trust Company, N.A transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Cetera Trust Company, N.A holds 5,775 shares of HALO stock, worth $339,512. This represents 0.23% of its overall portfolio holdings.
Number of Shares
5,775
Previous 5,625
2.67%
Holding current value
$339,512
Previous $269 Million
37.03%
% of portfolio
0.23%
Previous 0.17%
Shares
4 transactions
Others Institutions Holding HALO
# of Institutions
555Shares Held
124MCall Options Held
668KPut Options Held
259K-
Black Rock Inc. New York, NY17.6MShares$1.04 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$781 Million0.01% of portfolio
-
State Street Corp Boston, MA7.18MShares$422 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.17MShares$245 Million4.34% of portfolio
-
Bank Of America Corp Charlotte, NC3.45MShares$203 Million0.01% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.19B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...